1. Introduction {#sec0001}
===============

*Pasteurella multocida* is a small nonmotile gram-negative coccobacillus located in the upper portion of the porcine respiratory tract which, although is part of the commensal organisms, also can induce pneumonia in growing and finishing pigs. In this respect, *P. multocida* is regarded as a secondary opportunistic agent of the porcine respiratory disease complex (PRDC), which is one of the most common diseases of porcine intensive production ([@bib0002]). Besides, it is one of the organisms most commonly isolated from pneumonic lesions in pigs as primary agent of haemorrhagic septicaemia ([@bib0009]) caused by *P. multocida* B:2 ([@bib0019]) or E:5 ([@bib0008]). In addition, *P. multocida* may induce atrophic rhinitis along with *Bordetella bronchiseptica* ([@bib0016]). It has been separated into four subspecies on the basis of fermentation of sorbitol and dulcitol ([@bib0026]), being *P. multocida* subsp*. multocida* the only species of interest in diseases of swine.

The usage of antimicrobial agents, such as β-lactams, sulphonamide + trimethoprim (cotrimoxazol), florfenicol, macrolides and tetracyclines remains to be the best treatment to control PRDC ([@bib0006], [@bib0020]). This application has the capability to select for these compounds and gives rise to the development of resistances ([@bib0001]). So, resistance to antimicrobial agents used to inhibit the growth of *P. multocida* has been determined previously in disorders caused by this pathogen isolated from different countries ([@bib0017], [@bib0031], [@bib0034], [@bib0037]). In this respect, *tet*B gene has been previously detected respectively in 25% and 20% isolates ([@bib0007], [@bib0021]) and the presence of *bla*~ROB-1~ and *bla*~TEM-1~ genes has been also reported ([@bib0003], [@bib0007]). However, *erm*A, *erm*C, *msr*E or *mph*E genes were not found among 20 Australian isolates ([@bib0007]).

The objective of this study were to determine the *in vitro* antimicrobial susceptibility of clinical isolates of *P. multocida* recovered in Spain from November 2017 to April 2018. from slaughterhouses and to characterize the potential presence of resistant genes to antimicrobials on the part of the isolated strains and their putative association to resistance.

2. Materials and methods {#sec0002}
========================

2.1. Bacterial isolates {#sec0003}
-----------------------

The *P. multocida* isolates tested were obtained from 60 lungs with pneumonic lesions coming from pigs from "Castilla y León" which were slaughtered between November 2017 and April 2018 at the abattoir of the "Embutidos Rodríguez" corporation, placed in "Soto de la Vega" (León, northwestern Spain). *P. multocida* isolates were recovered on Columbia agar with 5% sheep blood (Oxoid). The strains were identified according to standard phenotypic procedures -gram stain, catalase, cytochrome oxydase and API 20-NE strips- ([@bib0023]) and they were then genetically confirmed by a specific species PCR assay ([@bib0035]), which also allowed the determination of the capsular type A or D ([@bib0036]).

2.2. Agar disk diffusion method {#sec0004}
-------------------------------

β-lactams, cephalosporins, fenicols, lincosamides, macrolides, quinolones, tetracyclines and sulfonamides were the groups of antimicrobials agents compared in this study. All the isolates were tested for their antimicrobial susceptibility by the disk diffusion method according to the performance standards M31-A3 of the [@bib0004]. Each strain was tested against eight selected agents: ampicillin (10 μg), cefotaxime (30 μg), chloramphenicol (30 μg), clindamycin (2 μg), erythromycin (15 μg), enrofloxacin (10 μg), tetracycline (30 μg) and sulfamethoxazole + trimethoprim (23.75 μg + 1.25 μg) (cotrimoxazol). *Escherichia coli* ATCC 25,922 and *Staphylococcus aureus* ATCC 25,923 were used as quality control (QC) strains. The interpretation of results was based on the breakpoints provided by the CLSI guidelines ([@bib0005]).

2.3. Detection of antimicrobial resistance genes {#sec0005}
------------------------------------------------

The detection of the resistance-associated genes to antimicrobial agents were carried by PCR, as described by [@bib0007], with all 32 *P. multocida* recovered. A total of eight antimicrobial resistance genes, belonging to three different families (*tet*A and *tet*B, *bla*~ROB-1~ and *bla*~TEM~, and *erm*A, *erm*C, *msr*E and *mph*E) were tested. The forward and reverse primers used were shown in [Table 1](#tbl0001){ref-type="table"}.Table 1Primers used in the PCR carried out for the detection of antimicrobial resistance genes in the 32 *Pasteurella multocida* isolates recovered in Castilla y León, northwestern Spain.Table 1Resistance genePrimerAmplicon sizeAnnealing temperature*tet*AF: 5′-GTA ATT CTG AGC ACT GTC GC-3′1,057 pb62 °CR: 5′-CTG CCT GGA CAA CAT TGT TT-3′*tet*BF: 5′CCT TAT CAT GCC AGT CTT GC-3′774 pb50 °CR: 5′ ACT GCC GTT TTT TTC GCC-3′*bla*~ROB1~F: 5′ CAT TAA CGG CTT GTT CGC-3′852 pb55 °CR: 5′-CTT GCT TTG CTG CAT CTT-3′bla~TEM~F: 5′GAG TAT TCA ACA TTT TCG T-3′856 pb55 °CR: 5′-ACC AAT GCT TAA TCA GTG A-3′*erm*AF: 5′-ACG ATA TTC ACG GTT TAC CCA CTT-A-3′610 pb53 °CR: 5-AAC CAG AAA AAC CCT AAA GAC ACG-3′*erm*CF: 5′-AAT-CGG CTC AGG AAA AGG-3′562 pb55 °CR: 5′-ATC GTC ATT TCC TGC ATG-3′*msr*EF: 5′-TAT AGC GAC TTT AGC GCC AA-3′271 pb58 °CR: 3′-GCC GTA GAA TAT GAG CTG AT-3′mphEF: 5'-ATG CCC AGC ATA TAA ATC GC-3'295 pb58 °CR:5'-ATA TGG ACA AAG ATAGCC CG-3'[^1]

3. Results {#sec0006}
==========

A total of 32 *P. multocida* clinical isolates were collected, ten (31.2%) of which came from León, eight (25.0%) from Segovia, and seven (21.8%) from each Valladolid and Zamora, all being provinces from "Castilla y León", Spain ([Fig. 1](#fig0001){ref-type="fig"}). From these, 31 (96.9%) belonged to capsular type A and only one (3.1%) to capsular type D. The MICs of the *E. coli* and *S. aureus* reference strains in each test were within the acceptable QC ranges of antimicrobial disk susceptibility test zone diameters.Fig. 1Geographical distribution of the 32 *Pasteurella multocida* isolates recovered in Castilla y León, northwestern Spain.Fig. 1.

Overall, 96.9% isolates (*n* = 31) were resistant to one or more antimicrobial agents, in such a way that 29.0% (*n* = 9) showed resistant to only one compound; 42.0% (*n* = 13), to two drugs and 29.0% (*n* = 9), to three antimicrobial agents. No strains were resistant to more than three compounds. The capsular type D was resistant to only one antibiotic (clindamycin). A total of 16 antimicrobial resistance patterns could be seen: 84.4% isolates (*n* = 27) were resistant to at least two antimicrobials, and 46.9% (*n* = 15) to a combination of three drugs. The 65.6% of strains (*n* = 21) were resistant simultaneously to the combination of clindamycin and cotrimoxazol, and the 18.7% (6 isolates each) behaved as resistant at the same time to clindamycin and cotrimoxazol along with ampicillin or erythromycin ([Table 2](#tbl0002){ref-type="table"}).Table 2Patterns of antimicrobial resistance among the 32 *Pasteurella multocida* isolates recovered in Castilla y León, northwestern Spain.Table 2No of isolatesNo. of antimicrobial agentsResistance patterns10No antimicrobial resistance21CLI (S to the remaining antimicrobials)31CLI (I to ERY)31CLI (I to AMP + ERY)11AMP (I to CLI + COT + ERY)82CLI + COT (I to ERY)22CLI + COT (I to ERY + AMP)22CLI + TET (I to COT + ERY)12CLI + ERY (I to COT)12CLI + ERY (I to AMP + TET)12CLI + COT (I to TET + CEF + CLO)33CLI + COT + AMP (I to ERY)13CLI + COT + AMP (I to ERY + CEF + CLO)13CLI + COT + ERY (I to CEF)13CLI + COT + TET (I to AMP + ERY + CEF)13CLI + COT + ERY (I to TET)[^2]

All isolates were susceptible to enrofloxacin, followed by chloramphenicol, cefotaxime and tetracycline, to which 93.8%, 87.5% and 81.2% of clinical strains showed susceptibility *in vitro*, respectively. On the other hand, 96.9% of them were resistant to clindamycin and 68.7% to cotrimoxazol. The most common behaviour of erythromycin to the 32 isolates surveyed was intermediate susceptibility, with inhibition zone diameters comprised between 14 and 21 mm. The rate of resistant or susceptible isolates to this antibiotic was quite similar, with four and three strains, respectively ([Table 3](#tbl0003){ref-type="table"}).Table 3Antimicrobial susceptibility of 32 *Pasteurella multocida* isolates recovered in Castilla y León, northwestern Spain, by disk diffusion test.Table 3Antimicrobial agentSusceptible (no of isolates)Intermediate (no of isolates)Non-susceptible (no of isolates)CLI3.1% (1)096.9% (31)COT31.2% (10)068.7% (22)AMP59.4% (19)040.6% (13)ERY9.4% (3)8.1% (25)12.5% (4)TET81.2% (26)018.8% (6)CEF87.5% (28)12.5% (4)0CLO93.8% (30)6.2% (2)0ENR100% (32)00[^3]

Concerning molecular basis of antimicrobial resistance to the 32 *P. multocida* isolates, the complete patterns are shown in [Table 4](#tbl0004){ref-type="table"}. No strains were positive for tetracycline resistance *tet*A gene, being the only one that was not amplified. A percentage of 40.6% of isolates (*n* = 14) was positive for *tet*B gene, but none of them were detected in resistant strains. With regard to β-lactam resistance genes, 40.6% of clinical strains (*n* = 14) were positive to *bla*~ROB1~ while only 12.5% (*n* = 4) were to *bla*~TEM~. Globally, 53.1% isolates (*n* = 17) showed some of these two β-lactam genes, and only one showed both of them. From the strains harboring any of the β-lactam resistance genes, only four exhibited resistance to ampicillin.Table 4Resistance genes harboured by the 32 *Pasteurella multocida* isolated in Castilla y León, northwestern Spain.Table 4Castilla y León counties and number of isolates (n)Resistance genes:*tet*A*tet*B*bla*~ROB-1~*bla*~TEM~*erm*A*erm*C*mph*E*msr*ELeón (10)01710314Segovia (8)07006601Valladolid (7)02600607Zamora (7)04132500**Total**0 (0%)14 (40.6%)14 (40.6%)4 (12.5%)8 (25.0%)20 (62.5%)1 (3.1%)12 (37.5%)

A considerably higher number of isolates (84.4%, 27 isolates) showed resistance genes to any of the macrolides. So, although *mph*E was only amplified in 3.1% of them (1 isolate), 25.0% (*n* = 8) were positive to *erm*A, a figure that reached to 37.5% (*n* = 12) when *msr*E was tested; finally, 62.5% (20 isolates) were positive to *erm*C. Only one of the isolates harboring *erm*A gene was resistant to erythromycin; other harbored *msr*E gene; a third one harbored *erm*A and *erm*C genes, and other one harbored *msr*E and *mph*E genes.

The *P. multocida* capsular type D exhibited only *msr*E gene. On the other hand, six of the eight strains recovered in Segovia showed the same resistance behaviour, being positive to *tet*B, *erm*A and *erm*C, and negative to the remaining five other genes; the seventh one exhibited only *msr*E, and the eighth one showed any of the eight resistance genes compared. A rate of 9.4% (3 isolates), two from Valladolid and the other one from Zamora were positive simultaneously to four of the genes tested; 37.5%, (*n* = 12) to three of them, and 34.4% (*n* = 11) to two of them both at once. Only 18.7% (6 isolates) showed one of the eight genes tested.

4. Discussion {#sec0007}
=============

*In* examining the results of this study, a number of issues can be taken into account. Firstly, it is necessary to bear in mind that this investigation relies on a collection of 32 *P. multocida* isolates from northwestern Spain. For this reason, a larger study would be required to gain insight into the national landscape in Spain; however, it must be assessed that this investigation was performed in the same region and slaughterhouses in which the works performed 14 and 20 years ago took place. Secondly, since the samples were obtained at the abattoir, but it is renown enough that Spain is one of the countries in all Europe where the major antibiotic expense takes place ([@bib0011], [@bib0013]), it is highly likely that the pigs (and consequently clinical isolates) used in this study originated from farms exposed to an extensive antimicrobial treatment.

Clindamycin resistance has previously been seen in *P. multocida* isolates in Spain both 20 and 14 years ago, when 63 and 132 isolates respectively had MIC values higher than the highest concentration tested, thus suggesting a high level of resistance or a completely inactivity to this lincosamide antibiotic ([@bib0037]). Similarly, a 100% resistance rate among 29 clinical isolates was reported by other investigators to this drug ([@bib0014]). Other *P. multocida* has been also found completely resistant to other lincosamide, lincomicycin ([@bib0038]). Slightly lower resistance rates (80.3%) have been cited for clinical strains recovered in China ([@bib0034]). However, some isolates largely susceptible to clindamycin have been detected in recent studies ([@bib0028]).

When comparing the results obtained in the current study for sulfamethoxazole + trimethoprim with those reported previously in Spain, it can be concluded that the resistance percentage is much higher now than 20 years ago. However, it was ten points lower than 14 years ago ([@bib0037]), thus indicating that resistance pressure to this combination of two drugs has not been high over the two last decades in Spain. Resistance values for cotrimoxazol reported in earlier studies ([@bib0029], [@bib0034]) were substantially higher (67.5% and 74.2%, respectively) than those observed in the current work. Quite different, hardly or no resistant isolates (2% and 0%, respectively) were found in other studies ([@bib0006]; de Jong et al., 2014).

Ampicillin exhibited efficacies over 97.0% two decades ago in Spain ([@bib0037]). The fact that in our study the susceptibility decreased to 59.4% clearly states that the wide use of this antibiotic and of β-lactams in general in treatment and prevention of respiratory tract disorders of swine has exerted a high selective resistance pressure on *P. multocida* isolates. This resistance can be mainly linked with the fact that these isolates would harbour the *bla*~ROB1~ resistance gene, which is widely carried by different human or animal genera of family *Pasteurellaceae*, such as *P. multocida* ([@bib0007], [@bib0031]), *Actinobacillus pleuropneumoniae* ([@bib0007]; Matter et al., 2007) or *A. porcinotonsillarum* (Matter et al., 2007), *Haemophilus influenzae* ([@bib0007], [@bib0025]) or *Haemophilus* (*Glässerella*) *parasuis* ([@bib0007], [@bib0032]). As in our study, a low prevalence of strains harboring *bla*~TEM~ has been previously reported ([@bib0007]).

Most of the isolates recovered during the last century in Spain were susceptible to erythromycin ([@bib0037]) and, similarly, only 12.5% of them were resistant to this macrolide in this study. However, the most common pattern in this case was intermediate susceptibility. These data were in accordance with previous findings ([@bib0006], [@bib0017], [@bib0033], [@bib0034]), but other investigators ([@bib0030]) reported limited activity for erythromycin against *P. multocida*, and even others have found 100% resistance among the isolates recovered from the lungs of diseased pigs from June 2013 to May 2015 ([@bib0038]). In our study, resistance was associated with the presence of *erm*C, *msr*E, *erm*A or *mph*E genes, while this quality in erythromycin could not be related with any of these genes in Australian isolates ([@bib0007]). According to the data obtained, macrolide resistant genes tested in this work are the only ones that can be linked with the resistance shown for *P. multocida* isolates, because all harbored some of the four genes compared.

The rate of resistance to tetracyclines has not increased excessively from 1988 to nowadays, because in the former year was only 1.6% and 14.4% in 2004 for oxytetracycline ([@bib0037]), while raised to 18.8% 14 years later to tetracycline. Similar results have been obtained in a pan-Europan study (de Jong et al. 2014) and in another one carried out in Poland ([@bib0024]), but higher values have been seen in most of the previous reports ([@bib0006], [@bib0029], [@bib0028], [@bib0033], [@bib0034], [@bib0038]). The resistance of *P. multocida* has been related with some genes, such as *tet*B, *tet*H and *tet*M, being *tet*H gene the most widespread ([@bib0018], [@bib0021], [@bib0031]). Only *tet*A and *tet*B genes were tested in our study, but no genes of the former one were found while *tet*B gene was encountered in 40.6% of isolates. Similar results were reported recently ([@bib0007]), while a considerably lower resistance (25.0%) associated to *tet*B genes has been already detected ([@bib0021]).

A comparable behaviour has been seen in Spain for the last 30 years for cefotaxime, a third-generation cephalosporin ([@bib0037]). So, no resistance was observed in any of the isolates recovered in this period, although a total of 12.5% of strains recovered in 2018 were classified as of intermediate susceptibility. Close results were detected among Chinese ([@bib0034]), Australian ([@bib0006]), Czechs isolates ([@bib0027]), other ones coming from a pan-European study (de Jong et al., 2014), or among fourth-generation cephalosporins such as cefquinome ([@bib0033]). However, resistance rates above 22% were detected recently to ceftiofur among Brazilian isolates ([@bib0029]), and to cefazolin among Taiwanese isolates ([@bib0038]). Ceftiofur resistance has been linked to *bla*~TEM-1~, in such a way that this gene has been detected both in resistant and susceptible *P. multocida* isolates ([@bib0003]). In this respect, *bla*~TEM~ gene has been also detected in our study.

Chloramphenicol is known to produce major adverse effects in humans, and its use by mouth or by injection is only recommended when safer antibiotics cannot be used. An excellent effectiveness result was recorded in our study, with no resistant and only two intermediate isolates to it. Similar results were obtained for 36 isolated previously ([@bib0033], [@bib0034]). Other safer phenicol, florfenicol, that is used exclusively in veterinary patients for the therapy of pneumonia caused by *P. multocida* ([@bib0022]), was equally highly effective against clinical isolates ([@bib0006]; de Jong et al., 2014). Nevertheless, resistance to florfenicol in two German isolates, being associated to plasmid pCCK381 and *florR* gene, was described ten years ago ([@bib0022]). Besides, resistances beyond 91% were detected for the 62 Taiwanese isolates collected for two years ([@bib0038]).

The results obtained by us nowadays matched completely with those recorded in both 1987--1988 and 2003--2004 periods for enrofloxacin ([@bib0037]). In addition, this quinolone appears to have the highest *in vitro* activity against the isolates tested in our study, a finding that is in agreement with that previously reported by most authors (de Jong et al., 2014; [@bib0010], [@bib0012], [@bib0017], [@bib0028], [@bib0033]). However, in an investigation by [@bib0029], 22.5% of strains were found non-susceptible to enrofloxacin, and in other by [@bib0038] almost 62% of them were non-active to this quinolone.

A total of 16 resistance patterns could be obtained in this study, being CLI + COT the most common of all. A higher spread can be seen in 2018 than in previous investigations conducted in Spain because 56.2% of the profiles were only displayed by one *P. multocida* isolate while this fact was seen respectively in 42.8% and in 38.5% of the isolates recovered in 1988 and in 2004 ([@bib0037]). In a quite similar investigation, only five patterns were detected to 21 *P. multocida* isolates, but 60% of them were resistant to one combination ([@bib0006]). Five profiles were also encountered in other study, but all were combinations of two antimicrobial agents and each pattern contained more than ten isolates ([@bib0015]). Anyway, none of the resistance profiles seen in any of these previous reports overlapped with those 16 patterns showed in the present study. Finally, the fact that 84.4% of isolates has behaved as resistant to at least two of the antimicrobial agents tested evinces the need of restrictive and responsible usage of these compounds in animals, especially in those intended for human consumption, along with susceptibility testing of this pathogen.

5. Conclusion {#sec0008}
=============

This study has shown data about the antimicrobial resistance of Spanish *P. multocida* from swine source and provides a genetic explanation for the resistance to erythromycin. On the other hand, enrofloxacin, chloramphenicol, cefotaxime and tetracycline were highly active *in vitro* against these isolates and, consequently, they remain useful for treatment of swine pneumonia caused by this pathogen.
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[^1]: F: forward; R: reverse.

[^2]: CLI, Clindamycin; S, susceptible; I, intermediate behaviour; ERY, erythromycin; AMP, ampicillin; COT, sulphamethoxazole + trimethoprim (cotrimoxazol); TET, tetracycline; CEF, cefotaxime; CLO, chloramphenicol.

[^3]: CLI, Clindamycin; COT, sulphamethoxazole + trimethoprim (cotrimoxazol); AMP, ampicillin; ERY, erythromycin; TET, tetracycline; CEF, cefotaxime; CLO, chloramphenicol; ENR, enrofloxacin; R, resistant behaviour; I, intermediate behaviour.
